$3.41
0.00%
Nasdaq, Thu, Sep 11 2025
ISIN
US68386J2087
Symbol
OPT

Opthea Limited - ADR Stock price

$3.41
+0.00 0.00% 1M
+0.28 8.95% 6M
-0.52 13.18% YTD
+0.31 10.00% 1Y
-2.74 44.55% 3Y
-10.99 76.32% 5Y
+2.01 143.57% 10Y
+0.53 18.40% 20Y
Nasdaq, Closing price Thu, Sep 11 2025
+0.00 0.00%
ISIN
US68386J2087
Symbol
OPT
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$30.0k | $810.2k
EBITDA
- | $-86.0m
EBIT
$-155.9m | $-75.5m
Net Income
$-162.8m | -
Free Cash Flow
$-158.7m
Growth (TTM | estimate)
Revenue
-75.0% | 2,600.7%
EBITDA
- | 44.8%
EBIT
23.9% | 51.5%
Net Income
27.9% | -
Free Cash Flow
1.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -10,611.0%
EBIT
-623,532.0%
Net
-651,164.0% | -
Free Cash Flow
-634,628.0%
More
EPS
$-0.1
FCF per Share
-
Short interest
0.5%
Employees
33
Rev per Employee
$0.0
Show more

Is Opthea Limited - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Opthea Limited - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Opthea Limited - ADR forecast:

1x Buy
11%
3x Hold
33%
5x Sell
56%

Analyst Opinions

9 Analysts have issued a Opthea Limited - ADR forecast:

Buy
11%
Hold
33%
Sell
56%

Financial data from Opthea Limited - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.03 0.03
75% 75%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
119% 119%
96,933%
- Research and Development Expense 127 127
29% 29%
422,767%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -156 -156
24% 24%
-519,610%
Net Profit -163 -163
28% 28%
-542,633%

In millions USD.

Don't miss a Thing! We will send you all news about Opthea Limited - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Opthea Limited - ADR Stock News

Neutral
GlobeNewsWire
24 days ago
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, t...
Neutral
GlobeNewsWire
5 months ago
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Neutral
GlobeNewsWire
6 months ago
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceuti...

Company Profile

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

Head office Australia
CEO Frédéric Guerard
Employees 33
Founded 1984
Website opthea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today